search
Back to results

Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer (TAXIS01)

Primary Purpose

Non-small Cell Lung Cancer Metastatic

Status
Suspended
Phase
Phase 2
Locations
Saudi Arabia
Study Type
Interventional
Intervention
cisplatin, docetaxel
Sponsored by
National Guard Health Affairs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer Metastatic focused on measuring Lung cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically or cytologically proven non-small cell lung carcinoma
  • Stage IV metastatic non-small cell lung carcinoma or stage III with malignant pleural effusion.
  • Patient should not be eligible for customization chemotherapy (if available at participating institutions).
  • Having at least one measurable lesion
  • Patient has life expectancy of 12 weeks or greater.
  • Age > 18 years.
  • No prior systemic treatment for metastatic lung cancer. Adjuvant treatment given more than 1 year ago is acceptable.
  • WHO performance status 0-2 (See Appendix III )
  • Adequate organ function:

    • Hematology: Neutrophils > 2 x 10 9 /L, platelets > 100 x 10 9 /L
    • Hepatic function: Total bilirubin < 1.25 times the upper normal limits, ASAT (SGOT) < 2 times the upper normal limits
    • Renal function: Creatinine < 1.5 mg/dL; if value is higher than upper normal limit but less than 2 mg/dL, the creatinine clearance should be > 60min/ml.
  • Able to comply with scheduled follow-up and with management of toxicity
  • Signed informed consent from patient or legal representative
  • Negative urine pregnancy test (if indicated)

Exclusion Criteria:

  • Pregnant or lactating women or women of childbearing potential using inadequate contraception.
  • Uncontrolled brain metastatic disease. (CNS disease that is stable > 4 weeks after radiotherapy in lieu of steroids reduction is eligible).
  • Symptomatic peripheral neuropathy > grade 1 according to the NCI Common Toxicity Criteria Version 3
  • Other serious illness or medical condition:

    • Unstable cardiac disease requiring treatment
    • History of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures
    • Active uncontrolled infection
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening
  • Concurrent treatment with any other anti-cancer therapy
  • Contraindication of steroid drug administration
  • Past (up to 5 years) or concurrent history of other neoplasm except curatively treated non- melanoma skin cancer or in situ carcinoma of the cervix

Sites / Locations

  • King Abdul Aziz Medical City for National Guard Health Affairs

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cisplatin, Docetaxel

Arm Description

Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles

Outcomes

Primary Outcome Measures

Efficacy
Efficacy will be measured by calculating the following: Response rate using Response Evaluation Criteria for Solid Tumor criteria Time to Disease progression or Death Overall Survival

Secondary Outcome Measures

Progression free survival, safety
To determine progression free survival, median survival and 1 year survival of the studied population. To evaluate the Number of participants with Adverse Events and Serious Adverse Events.Safety will include 4 parameters to be collected for all patients who receive the study regimen which are: Adverse Events Laboratory Assessments Vital Signs Physical Examinations

Full Information

First Posted
March 19, 2011
Last Updated
May 12, 2016
Sponsor
National Guard Health Affairs
search

1. Study Identification

Unique Protocol Identification Number
NCT01356303
Brief Title
Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer
Acronym
TAXIS01
Official Title
A Phase II Study of Docetaxel Combined With Cisplatin as the First Line Chemotherapy in Patients With Metastatic Non-small Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Suspended
Why Stopped
Difficulty in enrolling patients
Study Start Date
March 2009 (undefined)
Primary Completion Date
August 2016 (Anticipated)
Study Completion Date
August 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Guard Health Affairs

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a phase II, open-label clinical study prospectively enrolling 40 metastatic patients with non small cell lung cancer. The study will enroll patients at King Abdulaziz Medical City, Riyadh. Sub-sites will be open for patient accrual in selected centers in the Kingdom.
Detailed Description
The cisplatin/docetaxel is established standard in the first line management of metastatic non small cell lung cancer in the United States, Europe and Asia. However, the safety and efficacy of this regimen was not studied systematically in Middle Eastern population. The aim of this study is to study the efficacy and safety of this regimen in our patient population

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer Metastatic
Keywords
Lung cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cisplatin, Docetaxel
Arm Type
Experimental
Arm Description
Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
Intervention Type
Drug
Intervention Name(s)
cisplatin, docetaxel
Intervention Description
All patients met the eligibility criteria will undergo treatment with chemotherapy. Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles.
Primary Outcome Measure Information:
Title
Efficacy
Description
Efficacy will be measured by calculating the following: Response rate using Response Evaluation Criteria for Solid Tumor criteria Time to Disease progression or Death Overall Survival
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Progression free survival, safety
Description
To determine progression free survival, median survival and 1 year survival of the studied population. To evaluate the Number of participants with Adverse Events and Serious Adverse Events.Safety will include 4 parameters to be collected for all patients who receive the study regimen which are: Adverse Events Laboratory Assessments Vital Signs Physical Examinations
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically proven non-small cell lung carcinoma Stage IV metastatic non-small cell lung carcinoma or stage III with malignant pleural effusion. Patient should not be eligible for customization chemotherapy (if available at participating institutions). Having at least one measurable lesion Patient has life expectancy of 12 weeks or greater. Age > 18 years. No prior systemic treatment for metastatic lung cancer. Adjuvant treatment given more than 1 year ago is acceptable. WHO performance status 0-2 (See Appendix III ) Adequate organ function: Hematology: Neutrophils > 2 x 10 9 /L, platelets > 100 x 10 9 /L Hepatic function: Total bilirubin < 1.25 times the upper normal limits, ASAT (SGOT) < 2 times the upper normal limits Renal function: Creatinine < 1.5 mg/dL; if value is higher than upper normal limit but less than 2 mg/dL, the creatinine clearance should be > 60min/ml. Able to comply with scheduled follow-up and with management of toxicity Signed informed consent from patient or legal representative Negative urine pregnancy test (if indicated) Exclusion Criteria: Pregnant or lactating women or women of childbearing potential using inadequate contraception. Uncontrolled brain metastatic disease. (CNS disease that is stable > 4 weeks after radiotherapy in lieu of steroids reduction is eligible). Symptomatic peripheral neuropathy > grade 1 according to the NCI Common Toxicity Criteria Version 3 Other serious illness or medical condition: Unstable cardiac disease requiring treatment History of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures Active uncontrolled infection Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening Concurrent treatment with any other anti-cancer therapy Contraindication of steroid drug administration Past (up to 5 years) or concurrent history of other neoplasm except curatively treated non- melanoma skin cancer or in situ carcinoma of the cervix
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abdulrahman Jazieh, MD/MPH
Organizational Affiliation
King Abdul Aziz Medical City for National Guard
Official's Role
Principal Investigator
Facility Information:
Facility Name
King Abdul Aziz Medical City for National Guard Health Affairs
City
Riyadh
ZIP/Postal Code
11426
Country
Saudi Arabia

12. IPD Sharing Statement

Learn more about this trial

Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer

We'll reach out to this number within 24 hrs